EPS for TOTAL S.A. (TOT) Expected At $1.18; AngioDynamics, Inc. (ANGO) Had 2 Analysts Last Week

April 21, 2018 - By Marguerite Chambers


Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. AngioDynamics had 23 analyst reports since July 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, January 4 report. The company was maintained on Monday, July 10 by Canaccord Genuity. The firm has “Neutral” rating by Sidoti given on Wednesday, September 23. Cantor Fitzgerald initiated AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, November 4 with “Buy” rating. The company was initiated on Friday, July 24 by KeyBanc Capital Markets. As per Sunday, August 6, the company rating was maintained by Canaccord Genuity. On Tuesday, November 10 the stock rating was downgraded by Raymond James to “Mkt Perform”. Barclays Capital initiated AngioDynamics, Inc. (NASDAQ:ANGO) rating on Wednesday, February 8. Barclays Capital has “Equal Weight” rating and $17 target. The firm has “Hold” rating by Canaccord Genuity given on Tuesday, July 18. The company was maintained on Thursday, September 28 by KeyBanc Capital Markets. See AngioDynamics, Inc. (NASDAQ:ANGO) latest ratings:

03/04/2018 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform Upgrade
02/04/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $16.5 New Target: $17 Maintain
29/03/2018 Broker: Canaccord Genuity Rating: Hold New Target: $17.0000 Maintain
04/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.5 Maintain
05/01/2018 Broker: Craig Hallum Rating: Hold Downgrade

Analysts expect TOTAL S.A. (NYSE:TOT) to report $1.18 EPS on April, 26.They anticipate $0.17 EPS change or 16.83% from last quarter’s $1.01 EPS. TOT’s profit would be $3.07B giving it 13.18 P/E if the $1.18 EPS is correct. After having $1.10 EPS previously, TOTAL S.A.’s analysts see 7.27% EPS growth. The stock increased 0.27% or $0.17 during the last trading session, reaching $62.2. About 1.11M shares traded. TOTAL S.A. (NYSE:TOT) has risen 13.19% since April 21, 2017 and is uptrending. It has outperformed by 1.64% the S&P500.

Among 24 analysts covering Total SA (NYSE:TOT), 13 have Buy rating, 1 Sell and 10 Hold. Therefore 54% are positive. Total SA had 40 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of TOTAL S.A. (NYSE:TOT) earned “Hold” rating by Piper Jaffray on Tuesday, November 21. The stock has “Buy” rating by Credit Agricole on Tuesday, December 15. The stock has “Buy” rating by Cowen & Co on Thursday, July 27. The stock of TOTAL S.A. (NYSE:TOT) earned “Buy” rating by Cowen & Co on Tuesday, October 24. Piper Jaffray maintained the shares of TOT in report on Monday, September 25 with “Hold” rating. The firm earned “Outperform” rating on Monday, September 28 by BMO Capital Markets. As per Wednesday, November 30, the company rating was downgraded by Credit Suisse. As per Friday, February 9, the company rating was upgraded by Bernstein. Jefferies upgraded the shares of TOT in report on Tuesday, January 12 to “Buy” rating. On Thursday, December 1 the stock rating was upgraded by Independent Research to “Buy”.

TOTAL S.A. operates as an integrated gas and oil firm worldwide. The company has market cap of $161.80 billion. The firm operates through three divisions: Upstream, Refining & Chemicals, and Marketing & Services. It has a 18.62 P/E ratio. The Upstream segment engages in the exploration and production activities in approximately 50 countries, and produces oil or gas in approximately 30 countries; gas activities, including purchase, sale, and shipping of liquefied natural gas ; and trading of liquefied petroleum gas.

Investors sentiment increased to 1.26 in 2017 Q4. Its up 0.09, from 1.17 in 2017Q3. It is positive, as 14 investors sold AngioDynamics, Inc. shares while 48 reduced holdings. 22 funds opened positions while 56 raised stakes. 33.90 million shares or 1.62% more from 33.36 million shares in 2017Q3 were reported. Thrivent For Lutherans holds 22,840 shares or 0% of its portfolio. Manufacturers Life The stated it has 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Prudential Financial Inc holds 356,881 shares. Arizona State Retirement System holds 0.01% or 61,711 shares. Gotham Asset Mgmt Limited Liability Corp has 27,707 shares. Axa holds 0.01% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 220,600 shares. Lapides Asset Mgmt Ltd Liability Corporation reported 439,900 shares. Morgan Stanley owns 133,148 shares for 0% of their portfolio. Bnp Paribas Arbitrage Sa reported 21,313 shares stake. Granahan Investment Management Ma accumulated 390,720 shares or 0.51% of the stock. 541,800 were accumulated by Renaissance Technologies. Perkins Capital Mngmt holds 46,850 shares or 0.75% of its portfolio. Tci Wealth Advsr accumulated 52 shares. Texas Yale Cap Corporation has invested 0.03% in AngioDynamics, Inc. (NASDAQ:ANGO). Gamco Investors Inc Et Al owns 50,000 shares.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $734.99 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 554.72 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

TOTAL S.A. (NYSE:TOT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: